Li, J.; Zhang, S.; Ye, C.; Liu, Q.; Cheng, Y.; Ye, J.; Liu, Y.; Duan, X.; Xin, L.; Zhang, H.;
et al. Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy. J. Pers. Med. 2022, 12, 261.
https://doi.org/10.3390/jpm12020261
AMA Style
Li J, Zhang S, Ye C, Liu Q, Cheng Y, Ye J, Liu Y, Duan X, Xin L, Zhang H,
et al. Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy. Journal of Personalized Medicine. 2022; 12(2):261.
https://doi.org/10.3390/jpm12020261
Chicago/Turabian Style
Li, Jiayi, Shuang Zhang, Chen Ye, Qian Liu, Yuanjia Cheng, Jingming Ye, Yinhua Liu, Xuening Duan, Ling Xin, Hong Zhang,
and et al. 2022. "Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy" Journal of Personalized Medicine 12, no. 2: 261.
https://doi.org/10.3390/jpm12020261
APA Style
Li, J., Zhang, S., Ye, C., Liu, Q., Cheng, Y., Ye, J., Liu, Y., Duan, X., Xin, L., Zhang, H., & Xu, L.
(2022). Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy. Journal of Personalized Medicine, 12(2), 261.
https://doi.org/10.3390/jpm12020261
